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INTRODUCTION 
Diabetes mellitus refers to a metabolic disorder with various 
etiologies which is characterized by chronic hyperglycaemia 
causingdisturbances of carbohydrate, fat and protein metabolism, 
resulting from relative or absolute deficiency of insulin or both. The 
long–termdeleterious effects of diabetes include development of 
microvascular complications like retinopathy (18%), nephropathy 
(23.2%), neuropathy (26%) and macrovascular complications like cardiac 
(21%), peripheral arterial (6.3%) and cerebrovascular disease (24.4%). 
Since diabetes is now affecting the major workforce of various 
populations all over the globe, it has major anddeleterious impact on the 
productivity of an individual as well as the nation. Diabetes and its 
complications has atremendousnegative impact on the economic potential 
of both the developed and the developing nations.  
This rises the issue of early diagnosis of diabetes in order to 
prevent the development of complications in order to improve the quality 
of life of the population.  
The potential utility of HbA1c in the diagnosis of diabeteswas first 
mentioned in the WHO report published in 1985.With more information 
regarding the diagnosis of diabetesbecame available, WHO along with 
IDF called upon for a joint expert meeting to review and update the 
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recommendations on diagnosis of diabetes mellitus in 2005 and to include 
HbA1c in the diagnostic armamentarium. 
Glycosylated haemoglobin (HbA1c) is produced by a ketoamine 
reaction occurring between glucose molecule and the valine in the N-
terminalend of ß-chains of the haemoglobin molecule. HbA1c levels 
helpclinicians to get an overall picture of the average blood sugar levels 
over a period ofweeks/months1. 
This is important for diabetics, because,the higher the HbA1c 
levels, greater the risk of developing complications of diabetes.Chronic 
hyperglycaemic states tends to elevate the values of HbA1cand it 
correlatespositively with the metabolic control2. According to 
theguidelinespublished by the American Diabetes Association (ADA), 
HbA1c should be kept < 7% in patients with diabetes. The values > 7% 
indicate an increased probability of diabetes – related complications, 
especially microvascular. 
When there is chronic hyperglycemia, the nonenzymaticglycation 
of haemoglobin increases. This nonenzymatic glycation of proteins 
occurring as a result of hyperglycemia,has pronounced effects on the 
structure and functions of proteins. The two factors which can affect the 
glycation of proteins are theconcentration of blood glucoseandthe half life 
of the protein3, the latter being constant as it is genetically determined. 
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Thus, the quantity of HbA1c is determined solely by the blood glucose 
concentration. 
Many studies have shown that the level of HbA1ccan be altered by 
various other factors apart from blood glucose values. One such factor is 
the quantity of iron in the blood. So, iron deficiency anemia, which is the 
most common of the microcytic anemias4 plays a significant role in the 
measurement of HbA1c. Thus, India being the diabetic capital of the 
world, along with microcytic anemia prevailing so common in the 
community, needs certain measures to prevent false reporting of diabetic 
cases. 
Thus, the main aim of our study was to determine whether the level 
of HbA1c increased/decreased among the anemic patients without 
diabetes. If so, theanemia has to be corrected before any diagnosticor 
therapeutic decision was made based on the HbA1c levels. 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES 
 
1. To estimate HbA1c levels in non-diabetic adults with microcytic  
anemia. 
 
2. To compare it with HbA1c levels of non-diabetic controls and 
thereby establish a correlation between MCV and HbA1c levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
THE RED BLOOD CELL 
 Mature erythrocytes are unique of all the cells of human tissues, 
because they lack nucluei and cytoplasmic structures like lysosomes, 
endoplasmic reticulum, mitochondria, golgi apparatus8 etc., Hence they 
are incapable of undergoing mitosis, protein synthesis or oxidative 
reactions.  
 They have a diameter of 7-8 microns and normally exist in the bi-
concave form. Their membranes are so elastic that they can squeeze 
through the capillaries attaining lesser diameters than the bi-concave 
structure and can rapidly resume their original structure.  
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MEMBRANE AND CYTOSKELETON: 
 The membrane of the erythrocyte is highly deformable. It is fragile, 
but its integrity is maintained by the cytoskeletal structures on its inner 
surface, which forms a lattice like structure scaffolding the red cell 
membrane, thus maintaining the shape of the red cell. The fluid mosaic 
model best explains the structure of the red cell memrane, consisting of a 
lipid bilayer which is traversed by several trans-membrane proteins. 
Lipids: 
 Most of the membrane lipids of the erythrocyte are either 
phospholipids or unesterified cholesterol. The phospholipids include 
aminophosphatides (phosphatidylethanolamine and phosphatidylserine) 
on the inner side and choline containing lipids (phosphatidylcholine and 
sphingomyelin) on the outer side. Cholesterol plays an important role of 
maintaining the fluidity of the membrane, thus making the membrane 
more viscous. 
Proteins: 
Transmembrane proteins: 
The two important proteins in the erythrocyte cell membrane 
include: 
• Anion exchanger protein 1 (AE1), also called as band 3 protein 
• Glycophorin A (GPA) 
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AE1 protein takes care of the facilitated transport of anions and 
glucose into the RBC. The extra-cellular domain of AE1 protein is 
heavily glycosylated and it bears the carbohydrate blood group antigens 
(ABO and I/i blood group antigens)9. AE1 protein also interacts with 
ankyrin and contributes to membrane stability. 
The GPA protrudes to the exterior surface, contributing much to 
the negative charge of the outer surface of the red cell membrane at 
physiological pH10. It bears the M and N blood group antigens and is the 
binding site for antigens of Plasmodium falciparum 
Other trans-membrane proteins include:  
• Rh proteins 
• glycophorin B which carries S/s blood group antigens. 
Cytoskeletal proteins: 
The important cytoskeletal proteins in the erythrocyte membrane include: 
• Spectrin 
• Ankyrin 
• Protein 4.1 
Spectrin is intertwined among itself and actin to form a lattice like 
network attaching to the inner surface of the red cell membrane. This 
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structure is a resilient structure that helps the RBC to resume its 
biconcave disc shaped structure after forces causing distortion of the 
membrane are removed11. 
Other minor cytoskeletal proteins include: 
• Protein 4.9 
• Tropomyosin 
• Tropomodulin 
• Adducin 
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CYTOPLASM: 
The major junk of the RBC cytoplasm is made up of haemoglobin. 
It contributes to about 90% of the dry weight of the RBC12. The next 
important cytoplasmic protein is the enzyme, carbonic anhydrase. 
The structure, functions and the bio-chemistry of haemoglobin 
molecule is discussed in detail later. 
 
Metabolic processes inside the erythrocyte: 
 The survival of the RBC depends upon their capacity to generate 
high energy Adenosine TriPhosphate (ATP) and reduced dinucleotides. 
Since the erythrocytes lack mitochondria, it is not possible for 
Kreb’s cycle to take place, so aerobic glycolysis does not occur. Instead, 
ATP is generated through the anaerobic glycolytic (Embden-Meyerhoff)  
pathway13. 
A constant supply of ATP is required for the RBC to keep the Na+-
K+ ATPase pump active, in order to drive out the Na+cation out of the cell 
and maintain the influx of K+ ion. Thus, Na+ ion iside the cell is extruded 
preventing hemolysis. 
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Thus the EMP pathway results in the production of only 4 
molecules of ATP and 2 molecules of NADP, which is significantly less 
than that produced from the aerobic glycolytic pathway14. 
 
11 
 
A large amount of 2,3 BPG is present in the erythrocytes, which is 
produced as a result of anaerobic glycolytic pathway. The rate of 
synthesis and degradation of 2,3 BPG is regulated by the Rapaport-
Luedberg shunt. 
 
 2,3 BPG plays an important role in regulating the oxygen binding 
capacity of the haemoglobin molecule.  
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A small amount of glucose entering the RBC is utilised in the 
pentose phosphate pathway. NADP (Nicotinamide Adenine Dinucleotide 
Phosphate) is the major product of this pathway.  
 
 
 NADP is important for the erythrocyte in terms of requirement, 
since it is the major source of hydrogen atoms required to reduce the 
oxidised glutathione15. Reduced glutathione is necessary to repair the 
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effects of spontaneous oxidation of sulfhydryl groups which damage the 
RBC membrane. 
 Spontaneous oxidation of ferrous iron in hemeoccurseveryday. The 
product is methaemoglobin, containing iron in the ferric state. 
Methaemoglobin is converted back to haemoglobin by enzymatic 
reduction, using the NADH generated in the anaerobic glycolytic 
pathway and NADPH generated in the pentose phosphate pathway16.  
 
The summary of the metabolic processes taking place in the red 
blood cell is give in the following diagram17. 
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FUNCTIONS OF THE RED BLOOD CELL: 
 The presence of erythrocytes enables blood to carry about 100 
times more oxygen than that could be transported by plasma alone. 
 Each gram of haemoglobin can carry 1.39 ml of oxygen, when it is 
fully saturated, the degree of saturation depending upon the oxygen 
tension (PO2) of the blood. The degree of oxygen bound to haemoglobin is 
given by the oxygen dissociation curve18. 
The oxygen dissociation curve (ODC): 
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 The ODC is sigmoidal in shape, thus implicating, the binding of 
oxygen to one heme molecule increases the binding of oxygen to other 
heme molecules. Thus the affinity for the last oxygen molecule is 100 
times greater than the binding of the first oxygen molecule19. This 
phenomenon is called as the co-operative binding of oxygen to 
haemoglobin. The reverse also holds good, (i.e) release of one oxygen 
molecule from heme, facilitates the release of oxygen. 
 
 One molecule of heme binds with 4 molecules of oxygen.20 
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HEMOGLOBIN 
 Haemoglobin is a red blood cell pigment which  is almost 
exclusively found in erythrocytes.  
 The normal concentration of Hb in blood is: 
  Males: 14-16 g/dl 
  Females: 12-14 g/dl21 
The two major functions of haemoglobin are: 
1. Delivers O2 from lungs to tissues 
2. Transports CO2 and protons back from tissues to lungs 
STRUCTURE OF HEMOGLOBIN: 
 Haemoglobin (mol. wt: 64, 450) is a tetrameric allosteric protein 
consisting of heme – the non protein part and globin – the apoprotein 
part22. 
Structure of globin: 
 It consists of 4 polypeptide chains of two different primary 
structures. The common form is HbA1 (α2β2). The four subunits are held 
together by non-covalent interactions.  
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Structure of heme: 
 It contains a porphyrin molecule (protoporphyrin IX) with iron at 
the centre to which the histidine group of the globin chain and one 
molecule of oxygen are attached, in a plane perpendicular to the pyrrole 
rings23. Protoporphyrin IX consists of 4 pyrrole rings to which 4 methyl, 
2 propionyl and 2 vinyl groups are attached.  
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HbA1c: 
 The rate of the glycation reaction is proportional to the hemoglobin 
concentration of the blood.And also, the accessibility of the side chain 
amino groups of hemoglobin for glucose is constant and so is the lifetime 
of the red blood cells. So, only the concentration of glucose should 
influence the concentration of HbA1c24. Accordingly, HbA1c would be a 
perfect proxy for blood glucose concentration over the lifespan of an 
erythrocyte. 
 
 
     Thus, HbA1c is HbA1,that is being glycated at the N-terminal amino 
group of the β chain of haemoglobin  (βN-1-deoxyfructosyl-
hemoglobin)25. 
 
20 
 
The relationship between HbA1c and plasma glucose level is 
complex. Many studies have shown that HbA1c is an surrogate marker 
forthe mean plasma glucose over the preceding weeks to months.  
Erythrocyte life span averages 120 days. The level of HbA1c in the 
blood is contributed  by all the circulating erythrocytes, from the oldest 
(120 days old) to the youngest. However, recent plasma glucose levels 
over the recent 3– 4 weeks earlier contribute more to the level of HbA1c 
than does the long past plasma glucose levels (3–4 months earlier). 
Therefore, HbA1c is just an average of blood glucose levels during the 
preceding 120 days25.  
Plasma glucose levels in the preceding 30 days contribute  to about 
50% to the final HbA1c result, and plasma glucose levels from 90–120 
days earlier contribute to just only 10% of the final value of  HbA1c 2. 
This explains the increase or decrease in the level of HbA1c with large 
changes in levels of blood glucose. 
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Thus, it is evident that it does not take 120 days to detect an 
appreciable change in HbA1c after a change in mean plasma glucose.Thus 
HbA1c is a marker for chronic hyperglycemia. 
There is evidence that wide fluctuations can occur in HbA1c levels 
between individuals which is not related to glycemic status of the 
individual, suggesting that there are “low glycators” and “high 
glycators”7.8. 
FPG when used alone, should be used with great caution as a 
measure of long-term glycemia. FPG tends to progressively 
underestimate HbA1c (and seven-point MPG) at increasing levels of 
plasma glucose.  
The data also suggest that the post-meal blood glucose contributes 
much to the HbA1c levels; however, all post-meal times are not equal in 
their contribution.  
Compared with the seven-point glucose profiles, post-breakfast 
blood glucose levels markedly overestimate the HbA1c levels, whereas 
post-lunch glucose levels show a relationship withHbA1c levels that is 
very much similar to that of mean plama glucose. A previous study also 
showed that in patients with type 2 diabetes, post-lunch plasma glucose 
levels is a better indicator of glycemic control than is FPG9. 
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VARIOUS METHODS OF HbA1c TESTING: 
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RED CELL INDICES 
The major red cell indices include: 
1. Mean Corpuscular Volume (MCV) 
2. Mean Corpuscular Hemoglobin (MCH) 
3. Mean Corpuscular Hemoglobin Concentration (MCHC) 
4. Red Cell Distribution Width (RDW) 
Mean Corpuscular Volume (MCV): 
It is an index of the volume of a single red blood cell. A subnormal 
MCV indicates microcytosis, while a supranormal MCV indicates 
macrocytosis. 
Mean Corpuscular Hemoglobin (MCH): 
It is a measure of the amount of haemoglobin per red blood cell. A 
subnormal MCH denotes hypochromic RBCs. 
Mean Corpuscular Hemoglobin Concentration (MCHC): 
It measures the average amount of Hb in the erythrocytes, in toto. 
A subnormal MCHC indicates, interference in the synthesis of Hb. An 
elevated MCHC indicates, dehydration of the erythrocytes26. 
The calculation of these indices is given by the following formulas: 
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Red Cell Distribution Width (RDW): 
 It is a quantitative assessment of the variation in the red cell 
volume. It is increased in nutritional anemias like iron deficiency anemia 
and megaloblasticanemia, while it remains normal in cases of other 
causes of microcytic and macrocytic anemias. 
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 It can be expressed in terms of Standard Deviation (RDW-SD), 
where the normal reference range is 39-46 fl, or as Co-efficient of 
Variation (RDW-CV), where the normal reference range is 11.6-14.0%. 
 The normal red cell indices are summarised below: 
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ANEMIA 
 Anemiais present when the haemoglobin level or the hematocrit in 
the blood is below the lower reference range for age and sex of the 
individual, the lower limit of normalcy being reduced during pregnancy22. 
CLINICAL MANIFESTATIONS OF ANEMIA: 
The common symptoms of anemia include: 
• Fatigue 
• Tiredness 
• Effort intolerance 
• Effort dyspnoea 
• Palpitations 
• Gidiness 
• Effort angina 
The most common sign of anemia is PALLOR. Pallor is usually 
absent if the haemoglobin level is more than 9 g/dl, and usually present if 
the haemoglobin level is less than 6 g/dl. 
Other signs of anemia include high output failure and congestive 
cardiac failure in late stages. 
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TYPES OF ANEMIA: 
Anemia can be classified based on: 
• Morphology 
• Pathophysiology 
Morphological classification: 
 Anemia is classified morphologically based on MCV and MCH. 
1. Microcytic Hypochromic Anemia: 
It is defined as MCV < 80 fl and MCH <27 pg. 
It includes the following disorders: 
• Iron deficiency anemia 
• Lead poisoning 
• Sideroblasticanemia 
2. Normocytic Normochromic Anemia: 
It is defined by MCV 80-100 fl and MCH >27 pg 
It includes: 
• Haemolytic anemias 
• Anemia of chronic disease 
• Acute/Chronic blood loss 
• Renal disease 
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• Bone marrow failure (post-chemotherapy, infiltration by 
tumours, etc.,) 
3. Macrocytic Anemia: 
It is defined by MCV >100 fl 
Some examples include the following: 
Megaloblastic: 
• Vit B12 deficiency 
• Folic acid deficiency 
Non – Megaloblastic: 
 Alcoholism 
 Liver disease 
 Myelodysplasia 
 Aplastic anemia 
Pathophysiological classification: 
1. Decreased production: 
• Abnormal bone marrow 
o Aplastic anemia 
 Congenital 
 Acquired 
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o Pure red cell aplasia 
 Congenital (Diamond Blackfan) 
 Acquired  
o Myelophthisis 
 Myelofibrosis 
 Leukemia 
 Cancer metastasis 
• Essential factors deficiency 
o Deficiency anemia 
 Iron 
 Vit. B12 
 Folic acid 
o Anemia in renal disease 
 Erythropoietin deficiency 
• Stimulation factor deficiency 
o Anemia of chronic disease 
o Anemia of hypopituitarism 
o Anemia of hypothyroidism 
• ineffective erythropoiesis 
o thalassemia 
o sideroblasticanemia 
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2. Increased destruction:  
• Haemolytic anemia 
o Intra – corpuscular defect 
 Membrane defects 
 Spherocytosis 
 Ovalocytosis 
 Elliptocytosis 
 Enzyme defects 
 G-6-PD 
 Phosphokinase 
 Haemoglobin defects 
 Thalassemia 
 Hemoglobinopathies 
o Extra – corpuscular defect 
 Mechanical  
 MAHA 
 Chemical & Physical 
 Infection 
 Antibodies 
 Hyperspleenism 
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• Blood loss 
o Acute blood loss 
 Trauma 
 GI bleeding 
o Chronic blood loss 
 Hypermenorrhoea 
 Parasitic infections 
Importance of blood film examination: 
• Low power view: information regarding type and number of 
leucocytes 
• High power view: 
o Dry lens: deviation of red cell morphology, atypical 
cells 
o Oil immersion lens: finer details of abnormal red 
blood cells and leucocytes 
Key features to be noted on smear examination regarding 
erythrocyte are: 
• Red cell size and shape 
• Red cell chromasia 
• Inclusions 
• Abnormal/Atypical cells 
• Reticulocytes  
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MICROCYTIC ANEMIA 
 Microcytic anemia is characterised by the presence of small RBCs 
on a peripheral smear study and MCV < 80 fl on laboratory studies. 
 
There is increased central pallor (i.e) more than 1/3rd of the 
diameter of the RBC 
The diagnostic algorithm of microcytic anemia is as given below: 
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DIABETES MELLITUS 
Diabetes mellitus (DM) is a metabolic disorder characterised by the 
presence of hyperglycemia27. Raised glucose levels in the blood may 
speed up the process of atherosclerosis through various  mechanisms such 
as oxidative stress and protein glycation of vessel walls, discussed in 
detail below. 
Complications of diabetes mellitus: 
Long term diabetes would lead to complications. They can be 
grouped into two types, as microvascular and macrovascular28. 
1. Microvascular complications: 
• Neuropathy 
o Autonomic 
o Sensory and motor 
• Nephropathy 
• Ocular 
o Macular edema 
o Retinopathy 
2. Macrovacular complications: 
Coronary artery disease 
Cerebrovascular disease 
Peripheral arterial disease 
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PATHOGENESIS OF COMPLICATIONS: 
 The pathogenic factors can be classified into two major categories 
namely, vascular and metabolic changes29. 
1. Vascular changes: 
• Reduced blood vessel contractility 
• Increased vascular permeability 
• Thickened basement membrane 
• Endothelial dysfunction 
• Increased factor VII, vWF& PGI 
• Increased fibrinogen, CRP, PAI-I 
• Neovascularisation  
2. Metabolic changes: 
• Aldose reductase activity (polyol-sorbitol pathway) 
• Diacyl glycerol – protein kinase C activation (myoinositol 
pathway)30 
• Formation of advanced glycation end products (AGE) 
• Formation of reactive oxygen species 
Of all the mechanisms listed above, advanced glycation end 
products have been proved to be most important mechanism bearing more 
implications and is a novel target of therapy and will continue in the 
future31. 
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A. POLYOL – SORBITOL PATHWAY: 
Glucose gets converted to sorbitol (polyol) by the action of aldose 
reductase which is later converted to fructose by the enzyme sorbitol 
dehydrogenase. The second step requires conversion of NAD to NADH 
resulting in the generation of reactive oxygen species, thus contributing to 
the pathogenesis of diabetes32. 
 
Conversion of sorbitol to fructose also results in the decrease 
inmyo-inositol, which later leads to activation of the protein kinase C 
(PKC) pathway.  
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B. PROTEIN KINASE C PATHWAY: 
          Reduced myoinositol and chronic hyperglycemia per se, 
stimulate protein kinase C pathway resulting in: 
• Increased vascular permeability 
• Increased vasoactive hormones 
• Basement membrane thickening33 
 
37 
 
Reduced myo-inositol affects the Na+-K+ ATPase pump, 
particularly in neurons, resulting in the accumulation of intacellular 
sodium. Thus the conduction velocity of the neurons are reduced, causing 
various forms of neuropathy ranging from autonomic to sensori – motor. 
Myo-inositol deficiency has also been implicated in the 
pathogenesis of retinopathy and cataracts34. 
 
C. ADVANCED GLYCATION END PRODUCTS (AGE): 
     Glycation is a chemical process involving modification of 
proteins with reduing sugars, thus indicating a possible association 
between hyperglcemia and a wide variety of tissue pathologies.  
     Glucose forms a chemically reversible product with the proteins 
called as Schiff’s base. The reducing sugars then react with the amino 
groups of the long lived proteins to produce non – enzymatic cross 
links. Formation of these cross-links occur at the end of the Maillard 
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reaction and those end products are called as Advanced Glycation End 
– products (AGE)35. 
 
 
39 
 
    AGEs are a group of complex, unstable, reactive compounds 
formed in excess in states of hyperglycemia. They alter the structural 
properties of tissue proteins and thereby reducing their susceptibility 
to catabolism36. 
    The quantity of these AGEs can be used as surrogate markers for 
predicting the complications of diabetes, for example the blood levels 
of HbA1c correlate with the development of retinopathy. 
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The summary of the pathophysiological changes taking place due 
to hyperglycemia is shown below37. 
 
 All the mechanisms result in the production of reactive oxygen 
species and thus mitochondrial injury at the cellular level, thus resulting 
in tissue changes. 
 High glucose produces super oxide anion from the endothelial 
cells, which may quench nitric oxide, a potent endothelial derived 
vasodilator. Oxidative stress also interferes with endothelial dependant 
relaxation and cell replication, all of which culminating in the vascular 
complications of diabetes mellitus. 
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SCREENING OF DIABETES MELLITUS 
Current recommendations suggest screening for diabetes mellitus in: 
• Asymptomatic men >45 yrs 
• Asymptomatic women >55 yrs 
• The screening of the Pacific and the Indo – Asian population 
should begin for: Men at 35 yrs 
Women at 45 yrs38 
Screening should be done once in 3 – 5 yrs depending on the risk. 
Screening for diabetes should begin at 25 yrs of age in people with 
the following risk factors: 
• Ischemic heart disease 
• Cerebro-vascular disease 
• Peripheral arterial disease 
• Long term treatment with steroids 
• Long term anti – psychotic use 
• BMI ≥ 30 (≥27 for Indo – Asian population) 
• Family history oftype 2 diabetes at an early age of onset in 
more than one first degree relative 
• Past personal history of GDM 
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Additional risk factors include: 
• Central obesity 
• Impaired glucose tolerance on previous assessment 
• Adverse lipid profile 
• High blood pressure 
• Polycystic ovary syndrome (PCOS) 
• Current smoker (or) have quit smoking within the last 12 months 
 
Children and young adults with BMI ≥ 30 (≥27 for the Indo – 
Asian population)  should be screened for diabetes if: 
• Family history of  type 2 diabetes at an early age of onset 
• Pacific or Indo – Asian ethinicity48 
 
HbA1c  plays an important role in the screening of diabetes 
mellitus. So it is prudent that HbA1c levels measured in any person 
should be sufficiently standardised and care has to be taken that no false 
positives or false negatives can be encouraged.  
 
 
 
 DIAGNOSIS OF DIABETES MELLITUS
ADA recommend
is as follows61: 
Abnormal glucose homeostasis is defined as:
(1) FPG of 100–125 mg/dL
(2) plasma glucose le
glucose challenge is termed 
(3) HbA1c of 5.7–6.4%. 
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ed criteria for  the diagnosis  of diabetes mellitus 
 
 is defined as impaired fasting glucose 
vels between 140 and 199 mg/dL following 
as impaired glucose tolerance 
 
 
(IFG)  
an oral 
(IGT) 
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An HbA1c of 5.7–6.4%, IFG, and IGT are not equivalents, but 
instead, it denotes the  individuals in all the three categories who are at a 
greater risk of progressing to type 2 DM and diabetes – related 
complications.People in these groups should be counseled about ways to 
decrease these risks40. 
The current criteria for the diagnosis of DM emphasizes the fact 
that either HbA1c or the FPG as the most reliable tests for identifying 
DM in asymptomatic individuals41. 
The following picture shows the spectrum of normoglycemia and 
hyperglycemia: 
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ROLE OF HbA1c IN DIABETES 
The results of the Diabetes Control and Complications Trial 
(DCCT) which was published in 1993, and the U.K. Prospective Diabetes 
Study, published in 1998 showed that the relationship between HbA1c 
levels and the risk for development of diabetic complications in patients 
with type 1 and type 2 diabetes, respectively. 
In patients with diabetes, reducing plasma HbA1c levels by 
glycaemic control would lower the risk ofmicrovascular and 
macrovascular disease.  
Patients without diabetes, but with sub-optimalHbA1c levels may 
still have a level of dysglycaemia that may not yet meet the diagnostic 
criteria of diabetes mellitus, but may yet still contribute to an adverse 
outcome. Plasma HbA1c would be a more useful test to identify such 
patients, who are at risk. 
Studies have shown that, increase in HbA1c of 1% corresponds to a 
20–30% increase in mortality or cardiovascular events.Thus, HbA1c 
resembles blood pressure or cholesterol in terms of the continuous 
relation with cardiovascular risk42. 
Protein glycation includes haemoglobin, plasma proteins, 
membrane proteins, lens proteins, etc., of which glycosylated HbA1c 
forms the major fraction (80%). 
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HbA1c serves as a reliable indicator of diabetes control over the 
past 90 days, effectiveness of treatment and risk of development of acute 
or long term complications. 
Normal HbA1c levels and their interpretation: 
Non-diabetic range 4.5-5.8% 
Risk of hypoglycaemia <4.5% 
Diabetic range >6.5% 
Pre-diabetic range 5.8-6.5% 
Approximate correlation between levels and mean plasma glucose 
levels: 
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ADVANTAGES OF HbA1c: 
• No need of fasting 
• Day to day variations in plasma glucose values is less 
• Less biological variability associated with HbA1c 
• Established relationship between HbA1c and the future risk of 
retinopathy 
• Simpler sampling and analysis requirements43 
 
FPG AND HbA1c : 
 Fasting plasma glucose is still considered a valid test for the 
diagnosis of people with type 2 diabetes, when HbA1c levels cannot be 
used. FPG can also be used when there is a discrepancy between two 
values of HbA1c. In such situations FPG would prove useful to clarify the 
diagnosis. 
 Thus, FPG is the preferred as the initial test if the patient has a 
specific condition or a complication that is most likely to alter the  HbA1c 
value. The criteria for diagnosis of diabetes with FPG and OGTT remains 
unchanged though. 
 The following table depicts the difference in FPG and HbA1c:  
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 Thus HbA1c has advantages over FPG, except in terms of cost, 
which is the limiting factor for using HbA1c in developing countries. 
 Another point of interest is values of FPG and HbA1c during 
illness. Any illness, as a response by the body, increases the blood sugar 
levels, thereby increasing the values of FPG. Whereas, the life span of the 
RBC is reduced in illness, thereby reducing the values of HbA1c. Other 
than this, the values of FPG and HbA1c go hand in hand to each other44. 
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The following table gives a comparision between the glucose assys and 
HbA1c: 
 Glucose assays HbA1c 
Patient preparation 
prior to collection of 
blood 
Stringent 
requirements 
None 
Processing of blood 
Separation and storage 
of plasma or serum 
sample minimally at 
40C 
Avoid conditions for 
> 12 hrs at 
temperatures >230C. 
otherwise keep the 
sample at 40C 
Measurement 
Widely available all 
over the world 
Not widely available 
all over the world 
Standardization 
Standardised to 
reference procedures 
Standardised to 
reference procedures 
Routine calibration Adequately done Adequately done 
Illness 
Increasess the  
concentration of blood 
glucose 
Shorten lifespan of 
RBC, and thus 
reduces HbA1c 
Hemoglobinopathies 
Little problem unless 
the patient is ill 
Interferes in the 
measurement 
Affordability 
Affordable in most 
low and middle 
income countries 
Not affordable in most 
low and middle 
income countries 
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FACTORS INFLUENCING THE MEASUREMENT OF HbA1c 
LEVELS: 
 
1. Erythropoiesis: 
• Increased HbA1c:  
o iron deficiency 
o vitamin B12 deficiency 
o decreased erythropoiesis 
• Decreased HbA1c:  
o administration of erythropoietin 
o iron supplementation 
o vitamin B12 supplementation 
o reticulocytosis 
o chronic liver disease 
2. Altered Haemoglobin structure: 
• Genetic or chemical alterations in haemoglobin structure:  
o haemoglobinopathies 
o HbF 
o Methaemoglobin (variable HbA1c) 
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3. Glycation of HbA1c: 
• Increased HbA1c:  
o Alcoholism 
o chronic renal failure 
o decrease in intra – erythrocyte pH 
• Decreased HbA1c:  
o aspirin 
o vitamin C and E 
o certainhaemoglobinopathies 
o increase in intra – erythrocyte pH 
• Variable HbA1c:  
o genetic determinants 
4. Erythrocyte destruction: 
• Increased HbA1c:  
o increased erythrocyte life span: Spleenectomy 
• Decreased HbA1c:  
o decreased life span of the erythrocyte:  
 haemoglobinopathies 
 spleenomegaly 
 rheumatoid arthritis 
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 drugs 
 antiretrovirals 
 ribavirin 
 dapsone 
5. HbA1cAssays: 
• Increased HbA1c:  
o Hyperbilirubinaemia 
o carbamylated haemoglobin 
o alcoholism 
o large doses of aspirin 
o chronic opiate use 
• Decreased HbA1c:  
o hypertriglyceridaemia 
• Variable HbA1c:  
o haemoglobinopathies 
 
Thus, false elevation of HbA1c levels are encountered when there 
is an increase in the RBC lifespan and any condition that shortens the 
lifespan of RBC is likely to decrease the HbA1c levels46. 
 
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 The study was conducted in the Department of Internal Medicine, 
Madras Medical College, Rajiv Gandhi Government General Hospital, 
Chennai – 600003. 
ETHICAL COMMITTEE APPROVAL: 
 Obtained. 
PATIENT CONSENT: 
 Obtained.  
DURATION OF THE STUDY: 
 6 months. 
STUDY DESIGN: 
 Case control study. 
SAMPLE SIZE: 
 100 cases. 
 100 controls. 
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INCLUSION CRITERIA: 
 Confirmed cases of microcyticanemia as evidenced by: 
1. Hb< 12 g/dl (women); < 13 g/dl (men). 
2. MCV < 80 fl. 
3. Peripheral smear showing microcytosis. 
 
EXCLUSION CRITERIA: 
1. Acute/Chronic blood loss 
2. Hemolytic anemia 
3. Hemoglobinopathies 
4. Chronic kidney disease 
5. Pregnancy 
6. Established diabetes 
7. Impaired fasting glucose 
8. Impaired glucose tolerance 
9. Family H/O diabetes 
10. Obesity 
 
SELECTION OF CASES: 
 Patients in the general medical ward meeting the inclusion and 
exclusion criteria were selected for the study. 
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CONTROLS: 
 Age and sex matched subjects who did not have microcytic anemia 
but still meeting the exclusion criteria were selected as subjects. 
DATA COLLECTION AND METHODS: 
A total of 100 cases and 100 controls from general medical ward/OPD 
are selected according to inclusion and exclusion criteria and patients 
were subjected to following investigations: 
1. Complete hemogram 
2. Peripheral smear study  
3. Fasting blood glucose (FBG)  
4. Post Prandial Blood Glucose (PPBG) 
5. Oral Glucose Tolerance Test (OGTT)  
6. Glycosylated hemoglobin (HbA1c) 
 
HbA1c levels was then compared between both the groups and its 
correlation with microcytic anemia was calculated. 
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METHODOLOGY: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Select 100 cases and 100 controls based on 
inclusion and exclusion criteria 
Patients were assigned into two groups, 
namely cases and controls 
HbA1c was performed in both the groups 
Compare levels in both the groups using 
INDEPENDENT T TEST 
Arrive at conclusion 
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STATISTICAL ANALYSIS: 
Data was entered in Microsoft Excel spread sheet and analysed 
using the software-Epidemiological Information Package 2002 (Epi-
INFO 2002)-developed by the centre of disease control and prevention, 
Atlanta for World Health Organisation. Range, Median, Mean, Standard 
Deviation and ‘p’ values were calculated using this package. Chi-square 
test was done to find out the significance of relationship between the 
groups. Statistical significance was considered if the ‘p’ value was below 
0.05. 
  
SPONSORSHIP: 
 No. 
 
CONFLICT OF INTEREST: 
 None. 
 
 
 
 
 
OBSERVATIONS AND RESULTS  
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OBSERVATION AND RESULTS 
 
AGE WISE DISTRIBUTION OF CASES AND CONTROLS 
 
 Age Group 
Total 
20-40 41-60 61-80 
Group 
Case 
Count 31 47 22 100 
% within group 31.0% 47.0% 22.0% 100.0% 
Control 
Count 24 42 34 100 
% within group 24.0% 42.0% 34.0% 100.0% 
Total 
Count 55 89 56 200 
% within group 27.5% 44.5% 28.0% 100.0% 
 
 Cases and controls were selected between age of 20 – 80 yrs. 47% 
of the cases and 42% of the controls fell within the age group of 40 – 60 
yrs. 
 
 
 
 
 BAR DIAGRAM DEPICTING THE AGE DISTRI
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SEX DISTRIBUTION OF CASES AND CONTROLS 
 
 
SEX 
Total 
Male Female 
Group 
Case 
Count 49 51 100 
% within 
SEX 
49.5% 50.5% 50.0% 
Control 
Count 50 50 100 
% within 
SEX 
50.5% 49.5% 50.0% 
Total 
Count 99 101 200 
% within 
SEX 
100.0% 100.0% 100.0% 
 
The sex distribution between the case and controls were almost 
equal. 49.5% of the cases were males and 50.5% were females. 50.5% of 
the controls were males and 49.5% were females.  
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CASE AND CONTROL DEFINITION 
 
 
Hb Group 
Total 
Normal Anemic 
Group 
Case 
Count 0 100 100 
% within Hb 
Group 
0.0% 100.0% 50.0% 
Control 
Count 100 0 100 
% within Hb 
Group 
100.0% 0.0% 50.0% 
Total 
Count 100 100 200 
% within Hb 
Group 
100.0% 100.0% 100.0% 
 
          Cases were anemic patients, defined by Hb< 12 g/dl (for females) 
and < 13 g/dl (for males). Controls were non – anemic subjects. 
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CORRELATION BETWEEN MCV AND HbA1c 
 
HbA1c Group 
Total <6.5 
Normal 
>6.5 
Abnormal 
MCV 
Group 
50-60 
Count 0 6 6 
% within HbA1c Group 0.0% 7.0% 3.0% 
61-70 
Count 9 38 47 
% within HbA1c Group 7.9% 44.2% 23.5% 
71-80 
Count 6 40 46 
% within HbA1c Group 5.3% 46.5% 23.0% 
81-90 
Count 70 1 71 
% within HbA1c Group 61.4% 1.2% 35.5% 
above 
90 
Count 29 1 30 
% within HbA1c Group 25.4% 1.2% 15.0% 
Total 
Count 114 86 200 
% within HbA1c Group 100.0% 100.0% 100.0% 
Pearson Chi-Square=141.058*p<0.001 
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ANALYSIS OF MCV VALUES AND HbA1c 
 
44.2% of the patients with MCV values ranging between 61 – 70 fl 
had an abnormal HbA1c values > 6.5% and 46.5% of the patients with 
MCV values ranging between 71 – 80 fl had HbA1c values > 6.5%. 
  
61.4% of the patients with MCV values ranging between 81 – 90 fl 
had HbA1c values < 6.5% and 25.4% of the patients with MCV values 
above 90 fl had a normal HbA1c values < 6.5%. 
 
The effect of MCV values on HbA1c were analysed using the 
independent t test. The ‘p’ value obtained was <0.001 which is 
statistically significant. Thus proving, the lower the values of MCV 
below 80 fl, more the tendency for abnormal HbA1c (>6.5%).  
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CORRELATION BETWEEN Hb AND MCV 
 
 
Hb Group 
Total >12 
Normal 
<12 
Anemic 
MCV 
Group 
50-60 
Count 0 6 6 
% within Hb 
Group 0.0% 6.0% 3.0% 
61-70 
Count 0 47 47 
% within Hb 
Group 0.0% 47.0% 23.5% 
71-80 
Count 0 46 46 
% within Hb 
Group 0.0% 46.0% 23.0% 
81-90 
Count 70 1 71 
% within Hb 
Group 70.0% 1.0% 35.5% 
above 
90 
Count 30 0 30 
% within Hb 
Group 30.0% 0.0% 15.0% 
Total 
Count 100 100 200 
% within Hb 
Group 100.0% 100.0% 100.0% 
Pearson Chi-Square=196.056*p<0.001 
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ANALYSIS OF MCV VALUES AND Hb 
 
          47% of the patients with MCV values between 61 – 70 fl were 
anaemic (as defined by the criteria as mentioned above) and 46% of the 
patients with MCV values between 71 – 80 fl were anaemic. 
 
          70% of the patients with MCV values between 81 – 90 fl were 
normal and 30% of the patients with MCV values above 90 fl were 
normal. 
 
The effect of MCV values on Hb were analysed using the 
independent t test. The ‘p’ value obtained was <0.001 which is 
statistically significant. Thus proving, the lower the values of MCV 
below 80 fl, more the tendency for anemia (i.e) low Hb.  
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GROUP STATISTICS 
 
 Group N Mean 
Std. 
Deviation 
Std. Error 
Mean 
FBS 
Case 100 80.4000 9.30081 .93008 
Control 100 82.5200 8.07475 .80748 
PPBS 
Case 100 116.6600 9.45721 .94572 
Control 100 120.5100 11.45081 1.14508 
OGTT (2hrs) 
Case 100 114.7500 8.92208 .89221 
Control 100 120.2200 11.59727 1.15973 
 
 
 
 
 
 
 
 
 
 
 BAR DIAGRAM DEPICTING THE MEAN FBS
 
The FBS of the cases was 80.40 ± 9.30 mg/dl.
The FBS of the controls was 82.52 ± 8.07 mg/dl.
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 BAR DIAGRAM DEPICTING THE MEAN PPBS
 
The PPBS of the cases was 116.66 ± 9.45 mg/dl.
The PPBS of the controls was 120.51 ± 11.45 mg/dl.
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 BAR DIAGRAM DEPICTING MEAN OGTT (2 hrs)
 
The OGTT (2hrs) of the cases was 114.75 ± 8.92 mg/dl.
The OGTT (2hrs) of the controls was 120.22 ± 11.59 mg/dl. 
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GROUP STATISTICS 
 
 Group N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
Calculated 
t-Statistic 
Hb 
Case 100 10.0780 1.29985 .12999 
21.728* 
Control 100 14.2570 1.41880 .14188 
MCV 
Case 100 70.6930 5.85236 .58524 
23.895* 
Control 100 88.4560 4.58353 .45835 
HbA1c 
Case 100 6.8950 .55748 .05575 
24.573* 
Control 100 5.3560 .28544 .02854 
*p<0.001 
 
The ‘p’ value of the calculated t-statistic was <0.001, which is 
statistically significant 
 
 
 
 
 
 BAR DIAGRAM DEPICTING THE MEAN Hb
 
The Hb of the cases was 10.07 ± 1.29 g/dl
statistic of  21.728 
The Hb of the controls was 14.25 ± 1.41 g/dl with a calculated t
statistic of  21.728 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
case
74 
 with a calculated t
control
10.08 14.26
HB VALUE
 
-
-
 
case
control
 BAR DIAGRAM DEPICTING THE MEAN MCV
          The MCV of the cases was 70.69 ± 5.85 fl with a calculated t
statistic of  23.895 
          The MCV of the controls was 88.45 ± 4.58 fl with a calculated t
statistic of  23.895 
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 BAR DIAGRAM DEPICTING THE MEAN HbA
          The HbA1c of the cases was 6.89 ± 0.55 % with a calculated t
statistic of  24.573 
          The HbA1c of the cases was 5.35 ± 0.28 % with a calcula
statistic of  24.573 
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SCATTER PLOT BETWEEN MCV AND HbA1c 
 
 
          This scatter plot shows the inverse correlation between MCV and 
HbA1c.  
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SCATTER PLOT BETWEEN MCV AND Hb 
 
 
          This scatter plot shows the positive correlation between MCV  
and Hb.  
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PEARSON CORRELATION 
 
 
 
          The Pearson correlation between MCV andHbA1c is “-0.770” 
which signifies inverse correlation between the two variables, thus 
completing the aim of the study. 
          The Pearson correlation between MCV and Hb is “0.903” which 
signifies positive correlation between the two variables. 
 
 
 
 
 
 
 
 
 MCV HbA1c Hb 
MCV 
Pearson Correlation 1 -.770** .903** 
Sig. (2-tailed)  .000 .000 
N 200 200 200 
**. Correlation is significant at the 0.01 level (2-tailed). 
DISCUSSION 
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DISCUSSION 
A case control study was conducted in Institute of Internal 
Medicine at Rajiv Gandhi Government General Hospital, Chennai – 
600003 for a period of 6 months from April 2016 – September 2016. 
 100 cases and 100 controls were chosen from the general medical 
ward based on the inclusion and exclusion criteria as mentioned above. 
Fasting and post prandial blood sugars and OGTT were performed to all 
cases and controls in order to ensure that all those chosen for the study 
were only non – diabetic adults. After getting informed consent from 
them, all patients were subjected to detailed history taking, physical 
examination and relevant laboratory investigations. HbA1c levels was 
obtained from both the groups and compared using the independent t test. 
 HbA1c is commonlyused to assess the long-term blood sugar 
control in  diabetic patients, because HbA1cis a predictor of the risk for 
the diabetes – related complications, which has been shown by various 
studies. 
 Iron deficiency anemia is the most common form of  microcytic 
anemia and is the most prevalentanaemia worldwide. HbA1c is aglycated 
haemoglobin used to assess the glycemic status of patients with diabetes 
over the previous 3 months. Besides blood sugar, variousother conditions 
such as hemolyticanemias, hemoglobinopathies, hyperbilirubinemias, 
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iron, folate and vitamin B12deficiency, acute and chronic blood loss, preg-
nancy, chronic liver disease and uremia affect the levels of HbA1c. 
Recently, interest has arisen in studying the variations in HbA1c 
levelsthat are encountered in microcytic anemias like iron deficiency 
anemia. 
 The earliest study that investigated the effects of iron deficiency 
anemia on HbA1c levels was conducted by Brooks et al.,47in which 
HbA1c levels were assessed in 35 non-diabetic patients with iron 
deficiency anemia. Assessment of HbA1c valueswas done before and 
after treatment with iron. The observation was that HbA1c levels in iron 
deficiency anemia patients were higher and the HbA1c values decreased 
after treatment with iron. 
 It was proposed that, iron deficiency alters the quaternary structure 
of the hemoglobin molecule. Theglycation of the globin chain, in the 
relative absence of iron would occur more readily22. Sluiter et al.,46 tried 
to provide an explanation for the above mentionedfindings. They had 
proposed that the formation of glycated haemoglobin (HbA1c) within an 
erythrocyte was an irreversible process. Hence, the concentration of 
HbA1c within a singleerythrocyte would linearly increase with the age of 
the red cell. They also found out that in patients with euglycemia, but 
with very young red cells, a picture similar to that as would be found after 
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treatment of iron deficiency anemia, the HbA1c concentration was 
reduced. 
 Later, van Heyningen et al., reported that there was no differences 
in HbA1c concentrations compared to the non-diabetic patients with iron 
deficiency anemia before and after treatmentiron48. They also believed 
that the differences in HbA1c concentrations that were noted before and 
after iron supplementation were chiefly due to the differences in the 
laboratory methods used for measuring and calibrating HbA1c. 
 Raiet al., later investigated and came up with the conclusion that 
even though different methods are usedto measure HbA1c, no difference 
wasnoted among the colorimetric methods, ion-exchangechromatography 
and affinity chromatography51. 
 Hansen et al. also demonstrated that HbA1c levels tend to 
decreased upon treatment of the anemia53 adding evidence to the study 
done by Sluiter et al., This was thought to occur as a result of  increased 
bone marrow erythropoiesis which was brought about by the treatment 
with iron, thus leading to production of new immature erythrocytes from 
the bone marrow.They also showed that HbA1cconcentrations was 
normal in iron deficiency, which would dropdown tosubnormal levels 
after iron supplementation. 
83 
 
 Further studies conducted by El-Agouza et al., and Cogan et al.,49 
came up with the result stating that  HbA1c levels were higher in patients 
with iron deficiency anemia and would decrease on iron 
supplementation58. They argued that, elevated HbA1c levels in iron 
deficiency anemia was due to the fact that, if the serum glucose remains 
constant, a decrease in thehemoglobin concentration  increasesthe 
glycation of haemoglobin.  
 As is evident from the above studies, the mechanisms by which 
iron deficiency (microcytic)anemia affects HbA1c levels remains unclear. 
Since there are a large variations in the study results, we conducted our 
own study to investigate the effects of microcytic anaemia on HbA1c 
levels60. 
 In our study, 100 non diabetic cases and 100 non diabetic controls 
were selected and grouped based mainly on Hb and MCV values. Later 
HbA1c values were obtained from both the groups were compared using 
the independent t test. The correlation between MCV and HbA1c values 
was calculated using the Pearson co-efficient. The ‘p’ value of the test 
was <0.001, which is statistically significant with a Pearson co-
efficient of “-0.773”. So our study concludes that an inverse correlation 
exists between MCV values and HbA1c levels. So anemiaif present, must 
be corrected before any decision, whether diagnostic or  therapeutic,is 
made based on the HbA1c levels. 
LIMITATIONS 
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LIMITATIONS 
 
Our observations, since being made in a government general 
hospital, the study population chiefly belonged to a lower socio-economic 
class. Here, the causes of microcytic anemia, the major cause being iron 
deficiency anemia is not just bleeding and malabsorption, but also 
nutritional deficiency which may also have an impact on our study 
results. Other unknown variables such as racial, geographical factors also 
may influence our results. Further studies to confirm the roles of various 
other factors are needed to confirm our findings. 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
 
 Microcytic anemia definitely has an impact on the HbA1c. As 
MCV decreases in patients with microcytic anemia, HbA1c tends to rise.  
 
Thus, microcytic anemia, if present  must be corrected before 
making any diagnostic or  therapeutic decision based on the HbA1c 
levels. 
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ANNEXURES 
 
  
  
PROFORMA 
 
Name:      Age/Sex: 
Address:      Occupation: 
 
SYMPTOMS: 
Easy fatiguability  
Abdominal pain  
Abdominal distension  
Dyspnea  
Pedal edema  
Previous blood transfusions  
Malena  
 
PAST HISTORY: 
CAD  
CKD  
CLD  
 
PERSONAL HISTORY: 
SMOKING 
ALCOHOL 
 
FAMILY HISTORY OF DIABETES: 
 
GENERAL EXAMINATION: 
Pallor 
Icterus 
Cyanosis 
Clubbing 
Pedal edema 
Lymphadenopathy 
 
BMI: 
 
 
 
 
 
 
  
VITAL SIGNS: 
 PR- 
 BP- 
 RR- 
 JVP- 
 Temp- 
 
SYSTEMIC EXAMINATION: 
CVS: 
 
RS: 
 
ABDOMEN: 
 
 
CNS: 
 
INVESTIGATIONS: 
COMPLETE  HEMOGRAM: 
 Hemoglobin: 
 MCV: 
 MCH: 
 MCHC: 
 Hematocrit: 
 ESR: 
 
PERIPHERAL SMEAR: 
 
FASTING BLOOD GLUCOSE (FBG): 
 
POST PRANDIAL BLOOD GLUCOSE (PPBG): 
 
ORAL GLUCOSE TOLERANCE TEST (OGTT): Fasting: 
        1 hr: 
        2hr: 
 
HbA1c: 
 
  
  
 
 
 
 
 
 
  
TURNITIN PLIAGARISM SCREEN SHOT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
TURNITIN DIGITAL RECEIPT 
 
 
 
 
 
  
INFORMATION SHEET 
 
We are conducting a study on “EFFECT OF MICROCYTIC 
ANEMIA ON GLYCOSYLATED HEMOGLOBIN A1c IN NON-
DIABETIC ADULTS” among patients attending Rajiv Gandhi Government 
General Hospital, Chennai and for that your specimen may be valuable to us. 
The purpose of this study is to estimate HbA1c levels in non-diabetic adults with 
iron deficiency anemia and to compare it with HbA1c levels of non-diabetic 
controls. 
We are selecting certain cases and if you are found eligible, we may be 
using your blood samples to do certain tests which in any way do not affect 
your final report or management. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid in 
the management or treatment. 
 
 
 
Signature of Investigator 
 
 
 
Date: 
Place:
Signature of Participant 
 
  
 
  
CONSENT FORM 
 
 
Study Detail : “EFFECT OF MICROCYTIC ANEMIA ON 
GLYCOSYLATED HEMOGLOBIN A1c IN NON-
DIABETIC ADULTS” 
Study Centre : RajivGandhiGovernment GeneralHospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered to 
my complete satisfaction. ❏ 
b) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. ❏ 
c) I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to look 
at my health records, both in respect of current study and any further research that may 
be conducted in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any information released 
to third parties or published, unless as required under the law. I agree not to restrict the 
use of any data or results that arise from this study. ❏ 
d) I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperate with the study team and to immediately inform the 
study staff if I suffer from any deterioration in my health or well being or any 
unexpected or unusual symptoms. ❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo detailed clinical examination and blood 
investigations as required. ❏ 
 
 
Signature/thumb impression     Signature of Investigator 
 
 
Patient’s Name and Address:     Study Investigator’s Name: 
Dr. GOKHULA RAJ.B 
 
 
 
 
 
  
 
 
 
 
 
MASTER CHART 
 
SERIAL NO. CATEGORY AGE SEX FBS PPBS OGTT (2 hrs) Hb MCV HbA1c
1 CASE 45 M 97 116 120 10.5 72.7 6.8
2 CASE 34 M 76 107 104 9.5 66.5 6.5
3 CASE 57 F 89 121 115 9.4 68.6 5.5
4 CASE 47 M 98 135 124 6.5 57.4 7.1
5 CASE 38 M 92 120 116 8.5 72.5 8.2
6 CASE 78 F 89 136 119 11.5 76.4 6.6
7 CASE 34 M 78 123 129 12.4 78.3 6.6
8 CASE 65 M 87 104 114 11.2 78.2 6.8
9 CASE 34 M 84 109 104 8.3 72.8 6.9
10 CASE 35 F 94 137 107 9.2 63.2 5.7
11 CASE 65 M 78 113 114 9.7 57.6 6.7
12 CASE 43 M 84 106 104 10.6 74.7 6.5
13 CASE 42 F 80 122 118 11.4 79 6.9
14 CASE 76 F 94 121 127 9.6 64.2 6.9
15 CASE 73 F 75 109 108 8.9 67.8 7.3
16 CASE 56 F 85 116 114 7.9 69.5 5.9
17 CASE 52 F 93 118 131 8.6 70.9 6.4
18 CASE 56 M 67 104 103 10.4 78.3 6.8
19 CASE 62 M 75 109 120 9.7 77.7 6.7
20 CASE 38 F 72 115 118 9.3 68.5 6.9
21 CASE 42 M 79 132 112 10.8 75.2 6.6
22 CASE 38 F 84 106 107 11.3 76.8 6.4
23 CASE 63 F 78 118 136 9.7 72.7 8.4
24 CASE 53 M 83 105 103 12 79.1 7.4
25 CASE 28 M 92 114 106 11.7 75.3 6.6
26 CASE 48 F 86 108 114 10.6 72.8 6.8
27 CASE 53 F 85 128 119 9.8 62.8 7.8
28 CASE 72 M 72 119 124 11.4 69.4 6.7
29 CASE 58 F 75 124 105 10.4 73.5 6.9
30 CASE 68 M 81 114 109 9.7 53.4 6.9
31 CASE 46 F 90 107 113 7.9 75.9 8.2
32 CASE 55 F 74 114 101 10.5 69.3 6.7
33 CASE 60 M 84 117 108 11.3 68.4 6.8
34 CASE 34 F 93 109 124 9.4 74.5 7.6
35 CASE 72 M 69 114 127 10.6 64.4 6.8
36 CASE 50 M 78 123 118 11.7 69.4 6.6
37 CASE 37 F 70 118 108 10.4 77.9 7.1
38 CASE 52 M 89 129 103 6.8 52.8 7.5
39 CASE 47 F 79 108 134 10.4 78.3 6.9
40 CASE 58 F 82 103 115 7.6 64.8 7
41 CASE 40 F 90 123 107 9.5 72.6 7.4
42 CASE 36 F 75 133 108 11.3 75.8 6.7
43 CASE 52 M 84 114 113 7.3 67.5 6.9
44 CASE 45 F 76 124 108 11.8 72.6 7.3
45 CASE 69 M 83 113 117 8.2 59.7 8.2
46 CASE 70 M 96 135 109 10.6 69.3 6.7
47 CASE 38 M 74 113 131 11.9 71.4 6.8
48 CASE 46 F 80 125 119 10.3 68.4 6.9
49 CASE 26 F 64 120 113 9.6 64.8 7.3
50 CASE 36 M 79 119 124 9.4 75.7 6.3
51 CASE 35 M 78 128 104 7.3 74.6 6.7
52 CASE 56 F 87 116 115 8.3 59.5 7.4
53 CASE 57 F 83 105 135 10.5 75.2 6.8
54 CASE 74 M 67 138 114 11 64.3 7.8
55 CASE 35 F 79 123 124 11.5 77 6.7
56 CASE 57 M 63 118 105 10.4 67.2 6.8
57 CASE 65 F 79 108 103 9.4 67.5 7.3
58 CASE 27 M 85 129 118 8.9 69.3 5.7
59 CASE 74 F 63 114 104 11.6 78.4 6.4
60 CASE 45 F 84 105 118 10.7 73.5 6.9
61 CASE 75 M 73 130 105 11.3 74.5 7.8
62 CASE 56 M 69 114 114 9.6 69.4 7.6
63 CASE 24 F 66 112 117 10.5 70 6.9
64 CASE 47 M 72 132 126 11.3 77.3 6.7
65 CASE 48 F 84 104 106 9.4 64.7 6.1
66 CASE 38 M 59 121 108 11.3 74.2 6.5
67 CASE 48 F 93 108 118 10.8 69.3 6.9
68 CASE 56 M 73 115 125 9.4 68.4 7.3
69 CASE 27 F 95 122 130 10.3 63.5 6.9
70 CASE 36 F 78 104 113 10.5 68.2 5.3
71 CASE 46 F 72 119 108 11.3 70.7 6.8
72 CASE 54 M 69 120 115 9.6 86.3 6.8
73 CASE 54 F 83 129 132 10.2 70.5 6.9
74 CASE 48 M 82 105 104 11.3 78.2 6.9
75 CASE 37 F 63 118 122 10.5 75.7 7.3
76 CASE 73 M 84 115 118 6.2 62.7 8.1
77 CASE 54 F 78 136 105 11.6 72.5 6.8
78 CASE 56 M 75 104 114 8.9 65.3 6.9
79 CASE 67 M 89 126 104 9.5 66.4 7
80 CASE 32 F 83 117 118 10.7 64.8 6.7
81 CASE 56 M 93 104 103 11.5 71.9 6.8
82 CASE 37 M 92 137 124 9.9 70.4 6.2
83 CASE 73 F 96 113 117 11.3 74.6 5.8
84 CASE 38 M 82 104 132 10.4 74.1 6.6
85 CASE 63 F 73 107 116 9.5 69.4 6.8
86 CASE 28 F 58 119 104 10.7 68.4 6.9
87 CASE 48 F 74 121 124 11.3 74.8 6.6
88 CASE 38 M 83 116 119 11.8 77.3 7.4
89 CASE 57 M 60 120 104 10.4 78.1 7.2
90 CASE 59 F 85 114 126 8.6 67.3 6.8
91 CASE 61 F 72 102 114 10.4 69.8 6.9
92 CASE 47 M 83 116 126 10.4 70.6 6.6
93 CASE 47 F 95 108 117 9.4 63.8 8.1
94 CASE 34 M 73 104 104 11.7 75.7 6.8
95 CASE 43 M 76 118 112 10.5 73.5 6.6
96 CASE 27 M 89 125 107 11.6 73.5 6.9
97 CASE 59 F 85 105 115 9.5 69.4 6.7
98 CASE 24 F 91 105 106 10.4 70.7 7.8
99 CASE 59 F 76 113 115 9.3 68.5 6.8
100 CASE 77 M 85 110 104 8.4 69.1 6.6
SERIAL NO. CATEGORY AGE SEX FBS PPBS OGTT (2hrs) Hb MCV HbA1c
1 CONTROL 20 F 75 110 103 12.2 87.4 5.5
2 CONTROL 25 M 72 126 118 16.3 96.5 5.2
3 CONTROL 64 M 85 120 125 14.5 90.4 5.4
4 CONTROL 36 F 78 100 135 13.5 89.2 5.1
5 CONTROL 55 M 84 108 116 15.5 90.7 6.4
6 CONTROL 70 F 75 134 100 13.2 84.3 5.6
7 CONTROL 63 M 78 125 131 16.1 91.3 5.3
8 CONTROL 60 F 83 130 107 12.4 89.7 5.2
9 CONTROL 43 F 92 105 115 14.3 85.3 5.5
10 CONTROL 28 F 91 123 137 13.5 86.9 5.1
11 CONTROL 50 F 70 137 128 13.1 85.6 5.5
12 CONTROL 53 M 85 112 118 14.8 83.6 5.8
13 CONTROL 69 M 88 115 125 15.4 91.2 5.2
14 CONTROL 60 F 76 135 101 12.7 83.5 5.5
15 CONTROL 45 M 90 120 117 16.1 94.3 5.3
16 CONTROL 35 M 95 127 135 16.2 93.8 6.6
17 CONTROL 26 M 77 100 128 14.5 90.4 5.1
18 CONTROL 58 F 81 105 125 13.6 84.5 5.1
19 CONTROL 60 M 89 110 110 15.7 96.4 5.9
20 CONTROL 45 F 98 135 138 12.8 82.5 5.5
21 CONTROL 30 M 95 122 132 14.5 87.7 5.3
22 CONTROL 37 M 70 135 126 16.1 90.1 5.1
23 CONTROL 62 F 75 131 138 13.7 85.6 5.2
24 CONTROL 70 M 95 106 133 15 87.4 5.2
25 CONTROL 22 F 72 118 112 13.5 83.5 5.6
26 CONTROL 38 M 86 107 115 14.9 86.3 5.4
27 CONTROL 45 F 84 113 102 12.2 81.4 5.5
28 CONTROL 56 F 90 121 125 13.6 84.5 5
29 CONTROL 76 F 74 136 106 13.1 82.7 5.5
30 CONTROL 50 M 87 100 136 16.3 96.4 5.4
31 CONTROL 54 M 88 125 139 15.8 92.5 5.2
32 CONTROL 56 M 90 109 128 15.4 90.6 5.3
33 CONTROL 62 M 95 105 123 14.3 93.5 5.2
34 CONTROL 48 F 85 98 104 12.6 85.3 5.5
35 CONTROL 50 M 70 138 118 15.6 92.7 5.4
36 CONTROL 68 F 76 104 105 12.4 82.4 5.5
37 CONTROL 33 F 84 125 125 12.7 84.7 5.8
38 CONTROL 75 M 89 133 120 16.5 97.3 5.1
39 CONTROL 55 F 92 127 114 14.6 84.5 5.4
40 CONTROL 42 M 75 130 139 16.2 94.6 5.5
41 CONTROL 65 M 73 119 126 15.4 92.7 5
42 CONTROL 36 M 72 129 135 16.5 96.8 6.4
43 CONTROL 25 F 75 126 110 13.4 86.4 5.2
44 CONTROL 78 M 88 130 100 15.6 94.3 5.1
45 CONTROL 70 F 95 106 113 13.5 86.7 5.4
46 CONTROL 23 F 77 100 124 12.6 82.8 5.3
47 CONTROL 78 F 82 136 136 12.8 82.5 5
48 CONTROL 57 M 87 132 125 15.3 94.6 5.3
49 CONTROL 64 M 96 101 131 14.7 92.5 5.5
50 CONTROL 36 F 76 113 119 12.5 83.6 5.3
51 CONTROL 59 M 71 104 138 16.3 90.3 5.2
52 CONTROL 60 F 83 117 108 13.4 89.4 5.5
53 CONTROL 44 M 94 115 120 14.9 90.2 5.4
54 CONTROL 50 M 95 109 102 15.8 94.6 5
55 CONTROL 28 F 80 127 137 12.6 85.3 5.8
56 CONTROL 43 F 86 134 123 12.2 81.6 5.1
57 CONTROL 46 F 75 138 139 13 87.4 5.5
58 CONTROL 66 M 72 120 113 14.5 89.3 5.3
59 CONTROL 54 M 86 124 105 15.7 87.3 5.4
60 CONTROL 77 F 80 135 100 13.6 82.5 5.1
61 CONTROL 51 M 78 119 122 15.1 84.5 5.1
62 CONTROL 64 F 76 114 131 13 84.5 5.4
63 CONTROL 75 M 85 120 112 16.6 94.6 5.2
64 CONTROL 80 F 83 128 104 12.5 82.6 5.7
65 CONTROL 45 F 98 130 118 12.2 82.4 5.4
66 CONTROL 62 M 94 121 111 14.4 88.3 5.5
67 CONTROL 49 F 73 111 101 13.3 87.5 5.3
68 CONTROL 33 M 70 123 128 16.1 94.3 5.2
69 CONTROL 60 F 84 131 132 13.1 86.3 5.4
70 CONTROL 45 F 75 138 115 12.3 88.3 5.1
71 CONTROL 67 F 73 105 109 12.9 85.7 5.5
72 CONTROL 77 M 79 125 110 15.5 97.4 5.3
73 CONTROL 70 M 86 116 122 15.2 96.8 5.4
74 CONTROL 40 F 95 122 133 13.4 91.1 5.1
75 CONTROL 25 M 91 130 107 16.7 98.4 5.5
76 CONTROL 78 M 81 135 121 14.8 88.4 5.2
77 CONTROL 54 F 76 101 126 13.2 84.6 5.5
78 CONTROL 50 M 79 109 120 14.4 86.3 5.2
79 CONTROL 38 F 87 128 135 12.6 83.5 5.4
80 CONTROL 67 M 84 125 114 15.4 86.3 5.1
81 CONTROL 66 M 73 120 106 16.3 94.3 5.3
82 CONTROL 48 F 96 100 102 12.2 83.4 5.1
83 CONTROL 58 F 77 115 132 13.5 87.3 5.3
84 CONTROL 60 F 70 124 112 12.5 84.5 5.2
85 CONTROL 65 M 73 139 108 15 87.4 5.4
86 CONTROL 33 M 80 122 103 14.6 92.4 5.3
87 CONTROL 73 F 85 132 126 13.6 87.4 5.4
88 CONTROL 35 M 88 114 128 16.6 95.4 5.2
89 CONTROL 42 F 74 133 130 12.1 82.4 5.4
90 CONTROL 44 M 79 120 115 16.4 93.6 4.5
91 CONTROL 80 F 87 125 134 12.7 83.4 5.3
92 CONTROL 75 F 85 130 126 13.2 85.3 5.2
93 CONTROL 31 M 72 118 105 16.4 93.5 5.7
94 CONTROL 62 F 75 105 124 13.9 86.5 5.3
95 CONTROL 55 M 85 110 122 15.4 85 5.2
96 CONTROL 70 F 84 137 134 12.3 82.5 5.3
97 CONTROL 32 F 96 128 118 12.8 84.7 5.4
98 CONTROL 48 F 73 113 115 13.5 89.8 5.5
99 CONTROL 62 M 81 132 135 14.8 90.6 5.3
100 CONTROL 60 M 95 128 120 15.5 92.4 5.1
